Pyxis Oncology, Inc.
We are a preclinical oncology company focused on developing an arsenal of next-generation therapeutics to target difficult-to-treat cancers and improve quality of life for patients. We develop our product candidates with the objective to directly kill tumor cells, and to address the underlying pathologies created by cancer that enable its uncontrollable proliferation and immune evasion. Since our launch in 2019, we have developed a broad portfolio of novel antibody drug conjugate, or ADC, product candidates, and monoclonal antibody, or mAb, preclinical discovery programs that we are developing as monotherapies and in combination with other therapies.
We take a holistic view of attacking the key drivers of tumor growth and progression within the tumor microenvironment, or TME, including targeting of tumor antigens and modulating the innate and adaptive immune response. The TME is an immunosuppressive environment consisting of cancer cells and stroma, which includes the blood vessels, immune cells, fibroblasts, signaling molecules, and the extracellular matrix that surrounds the tumor. The TME plays multiple roles in tumor formation, progression and metastasis as well as anti-tumor immune activity. We are developing our ADC and mAb product candidates to precisely target key modulators of the adaptive and innate immune system within the TME for difficult-to-treat solid and hematologic tumors.
(Note: Pyxis Oncology further upsized its IPO at pricing on Oct. 7, 2021, by pricing 10.5 million shares – up from 9.5 million in the recently upsized prospectus – and priced the deal at $16 – the top of its $14-to-$16 range – to raise $168 million. Pyxis Oncology had upsized its IPO by 13.9 percent to 9.5 million shares, up from 8.34 million shares, and kept the price range at $14 to $16, in an S-1/A filing dated Oct. 7, 2021 – on the morning of its scheduled pricing date.)
|Address||35 CambridgePark Drive Cambridge, Massachusetts 02140, US|
|Phone Number||(617) 221-9059.|
|View Prospectus:||Pyxis Oncology, Inc.|
|Revenues||$0 mil (last 12 months)|
|Net Income||$-52.7 mil (last 12 months)|
|Price range||$16.00 - $16.00|
|Est. $ Volume||$168.0 mil|
|Manager / Joint Managers||BofA Securities/ Jefferies/ Credit Suisse/ William Blair/ LifeSci Capital|
|Expected To Trade:||10/8/2021|
|Quiet Period Expiration Date:||Available only to Subscribers|
|Lock-Up Period Expiration Date:||Available only to Subscribers|
|SCOOP Rating||Available only to Subscribers|
|Rating Change||Available only to Subscribers|